• Start
  • Cancer
  • Technology
    • Technology
    • Human Scaffolds
    • 3D Synthetic Scaffolds
  • Products & Services
  • Pipeline
  • News
  • Publications
  • Partners & Customers
  • About
Curing cancer by generating precision medicine Curing cancer by generating precision medicine Curing cancer by generating precision medicine Curing cancer by generating precision medicine
  • Start
  • Cancer
  • Technology
    • Technology
    • Human Scaffolds
    • 3D Synthetic Scaffolds
  • Products & Services
  • Pipeline
  • News
  • Publications
  • Partners & Customers
  • About

Archives

Monthly Archive for: "June, 2022"
Home » Archives for June 2022
11. The Effect of Hypoxic and Normoxic Culturing Conditions in Different Breast Cancer 3D Model Systems
0
By Per Setterberg
In Publication
Posted June 16, 2022

11. The Effect of Hypoxic and Normoxic Culturing Conditions in Different Breast Cancer 3D Model Systems

Publication showing that cells cultured on patient-derived scaffolds closely resembled cells cultured on 3D printed scaffolds, contrasting 2D and Matrigel-cultured cells, regardless of a normoxic [...]

READ MORE
10. -5-fluorouracil-treatment-of-patient-derived-scaffolds-from-colorectal-cancer-reveal-clinically-critical-information
0
By Per Setterberg
In Publication
Posted June 16, 2022

10. -5-fluorouracil-treatment-of-patient-derived-scaffolds-from-colorectal-cancer-reveal-clinically-critical-information

New publication showing how individual patient specific microenvironments influence the chemotherapy response in colorectal cancer. [...]

READ MORE
Recent Posts
  • Business Developer
    Business Developer
    May 1, 2024
  • Iscaffpharma’s first patent issued by the United States Patent and Trademark Office
    Iscaffpharma’s first patent issued by the United States Patent and Trademark Office
    January 26, 2024
  • SLAS honors Per Setterberg as fellow member
    SLAS honors Per Setterberg as fellow member
    October 19, 2023
Recent Publications
  • 17. Ovarian tumor cells gain competitive advantage by actively reducing the cellular fitness of microenvironment cells
    17. Ovarian tumor cells gain competitive advantage by actively reducing the cellular fitness of microenvironment cells
    December 16, 2024
  • 16. Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development
    16. Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development
    April 26, 2024
  • 15. Proteomics of cell-free breast cancer scaffolds identify clinically relevant imprinted proteins and cancer-progressing properties
    15. Proteomics of cell-free breast cancer scaffolds identify clinically relevant imprinted proteins and cancer-progressing properties
    April 4, 2024
Contact us
  • Org nr: 559120-9753
  • Iscaff Pharma AB
    Erik Dahlbergsgatan 11A
    411 26 Gothenburg
    Sweden
  • contact@iscaffpharma.com
Copyright All Rights Reserved © 2023
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt